Biopharmaceutical company focusing on the development and commercialization of therapies for central nervous system disorders.
Vanda Pharmaceuticals Inc. is a leading biopharmaceutical company dedicated to developing and commercializing therapies that address significant unmet medical needs. The company's current portfolio includes HETLIOZ, approved for non-24-hour sleep-wake disorders, and Fanapt oral tablets, indicated for schizophrenia treatment.
In addition to its marrketed products, Vanda Pharmaceuticals has a robust pipeline of developmental therapies. This includes expanding the potential indications for HETLIOZ to include jet lag disorder, Smith-Magenis syndrome, pediatric Non-24, autism spectrum disorders, and delayed sleep phase disorder. Fanapt is also being explored for bipolar disorder treatment, alongside a long-acting injectable formulation for schizophrenia management.
Among its promising investigational therapies is Tradipitant (VLY-686), a neurokinin-1 receptor antagonist targeted for conditions such as atopic dermatitis, gastroparesis, and motion sickness. The company is also advancing VTR-297, a histone deacetylase inhibitor, for potential use in hematologic malignancies and various oncology indications. Other compounds in development include VQW-765, a nicotinic acetylcholine receptor partial agonist, focusing on psychiatric disorders.
Founded in 2002 and headquartered in Washington, D.C., Vanda Pharmaceuticals operates on a global scale, marketing its products in the United States, Europe, and Israel. The company's commitment to advancing therapeutic solutions through innovative research underscores its mission to improve patient outcomes and redefine standards of care across diverse medical conditions.